C Diff Treatment

Risk factors for developing C. difficile-associated disease & the impact of the COVID-19 pandemic on the occurrence of C. difficile infection

There is no benefit of using vancomycin compared to metronidazole concerning recurrence rate requiring hospitalization, in-hospital and up to 4- and 8-week mortality rate in non-severe first episode of CDI.

Observational cohort.

Due to diverse roles of ClpP and the reliance of pathogens upon this system for infection, it has emerged as a target for antimicrobial development. Biology regulated by ClpP is organism dependent and has not been defined in Clostridioides difficile.

Fulminant Clostridioides difficile infection (FCDI) encompasses 3 to 5% of all CDI cases with associated mortality rates between 30 and 40%. Major treatment modalities include surgery and medical management with antibiotic and nonantibiotic therapies. However, identification of patients with …

I am a C. diff survivor. In June 2021 I went to the ER for a kidney stone. I passed it at the ER fairly quickly ( it was a small one). They tested my urine and did blood work, and said I didn’t have an infection but put me …

With a diagnosis of a C. difficile infection, dehydration can occur quickly.

Clostridium (Clostridioides) difficile infection (CDI) remains an urgent threat to patients in health systems worldwide. Recurrent CDI occurs in up to 30% of cases due to sustained dysbiosis of the gut microbiota which normally protects against CDI. Associated costs of initial and recurrent episodes …

Our results suggest that non-adherence with CDI treatment guidelines depends on the duration of symptoms and rapid EIA test results. Patients with an increased risk of recurrence were neglected.

Bezlotoxumab was associated with a meaningful reduction in recurrent CDI in this cohort largely comprising immunocompromised and transplant patients. Larger studies are warranted to evaluate bezlotoxumab in this population.

In February 2020 I was prescribed both clindamycin and cefalexin for a breast abscess. Three weeks after I finished my course of antibiotics, in March 2020, I started to have severe, painful abdominal cramping and diarrhea.  Each day became worse and worse until I was up through the night and …

A new orally delivered investigational therapy could help curb the costly and often recurring infection.

1. SER-109, an oral microbiome therapy, showed superiority over placebo in reducing the recurrence of C. difficile infection. 2. SER-109 resulted in the gastrointestinal microbiome and bile-acid profiles known to inhibit Clostridioides difficile (C. difficile) spore germination. Evidence Rating Level: 1 [Excellent] Study Rundown: C. difficile infection is a prevalent healthcare burden. It often occurs […]

After updating our health system's Clostridioides difficile treatment protocols in 2018, we reviewed 104 unique hospital encounters involving fidaxomicin at 10 community hospitals. Half (50%) of regimens were adherent to our guidelines, with infectious diseases (ID) providers were frequently nonadhe …

Nice @StanfordHealth study sharing experience discharging 15 patients on fidaxomicin for #CDiff - 80% had co-pays of $35 or less, 73% did not require prior authorization, and 30 day recurrence rate was 7% (1 out if 15). Does this match your experience? https://t.co/6GePeWM2M6— Michael Calderwood, MD, MPH (@CalderwoodMD) January 22, 2022

Background: Doxycycline possesses antibacterial activity against Clostridioides difficile and anti-inflammatory effects. Materials and Methods: The influence of doxycycline on the development of CDI was studied in an established animal model of CDI using C57BL/6 mice. Results …

Clostridioides (C.) difficile produces the exotoxins TcdA and TcdB, which are the predominant virulence factors causing C. difficile associated disease (CDAD). TcdA and TcdB bind to target cells and are internalized via receptor-mediated endocytosis. Translocation of the toxins' enzyme …

Infectious Disease News | New guidelines issued in 2021 stated a preference for fidaxomicin as first-line treatment for Clostridioides difficile infection, despite concerns about its cost. We asked Infectious Disease News Editorial Board Member Jeff Brock, PharmD, MBA, BCPS-AQ ID, an infectious disease pharmacy specialist at Mercy Medical Center in Des Moines, Iowa, if the new guidelines got it right.

Educating & advocating for c. diff. infection prevention and more worldwide

In this phase 3 RCT, the percentage of pts with recurrent #Cdiff was 12% in the SER-109 group and 40% in the placebo group (RR: 0.32; 95% CI: 0.18 to 0.58; P

Nine months ago my world was turned upside down. I was prescribed an antibiotic for a wisdom tooth procedure. Five days later I woke up to the worst pain of my life. After two days of pure misery crying on my bathroom floor, I went into urgent care. The doctor …

Interesting. Important to note ⬆️ vanc levels in human faeces are in xs of MICs. Ribotyping would answer whether expansion of single ribotype or more. @HCAILeeds and @SmitsLab optimising #Cdiff susceptibility testing methods in @ESCMID sponsored project. @EUCAST_EUCAST— Jane Freeman (@drjanefreeman) January 15, 2022

Nature Reviews Microbiology - Microbiome-based therapeutics hold great promise for reducing disease susceptibility and enhancing disease resistance. In this Review, Sorbara and Pamer explore the...

Background Neutropenia and antibiotic use put patients at risk for Clostridioides difficile infection (CDI) following allogenic hematopoietic cell transplant (alloHCT). CDI following alloHCT has bee...